MAVUPHARMA
Mavupharma is developing non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease.
MAVUPHARMA
Industry:
Biotechnology Health Care Life Science Pharmaceutical
Founded:
2016-01-01
Address:
Kirkland, Washington, United States
Country:
United States
Website Url:
http://www.mavupharma.com
Total Employee:
1+
Status:
Closed
Email Addresses:
[email protected]
Total Funding:
20 M USD
Technology used in webpage:
SPF Font Awesome Apache Microsoft Exchange Online Office 365 Mail Linode
Current Advisors List
Current Employees Featured
Founder
Investors List
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Series A - Mavupharma
Alpine BioVentures
Alpine BioVentures investment in Series A - Mavupharma
More informations about "Mavupharma"
Mavupharma - Crunchbase Company Profile & Funding
Mavupharma is developing non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease.See details»
Mavupharma Company Profile 2024: Valuation, …
Where is Mavupharma headquartered? Mavupharma is headquartered in Kirkland, WA. What is the size of Mavupharma? Mavupharma has 5 total employees. What industry is Mavupharma in? Mavupharma’s primary industry …See details»
AbbVie acquires Mavupharma, developer of small molecules that …
Jul 19, 2019 · AbbVie has acquired Mavupharma, a small Seattle-based biotech company, for an undisclosed sum. Mavupharma’s lead candidate is an inhibitor of an enzyme called ENPP1. Inhibiting that enzyme increases the activity of another protein known as STING, which itself …See details»
AbbVie acquires Mavupharma - 2019-07-15 - Crunchbase
Jul 15, 2019 · Mavupharma Non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease. Acquiring Organization: AbbVie AbbVie is a pharmaceutical company that discovers, develops, and markets medicines.See details»
AbbVie acquires STING-focused biotech | C&EN Global Enterprise
Jul 22, 2019 · AbbVie has acquired Mavupharma, a small Seattle-based biotech company, for an undisclosed sum. Mavupharma’s lead candidate is an inhibitor of an enzyme called ENPP1. Inhibiting that enzyme increases the activity of another protein known as STING, which itself …See details»
Mavupharma Inc - Company Profile and News - Bloomberg Markets
Mavupharma, Inc. operates as a pharmaceutical company. The Company develops drugs for the treatment of cancer and infectious diseases. Mavupharma serves clients in the State of Washington.See details»
AbbVie Enhances Early Stage Oncology Pipeline with Acquisition …
NORTH CHICAGO, Ill., July 15, 2019 / PRNewswire / -- AbbVie (NYSE: ABBV) announced today that it has acquired Seattle -based Mavupharma, a privately held biopharmaceutical company focused on novel approaches to target the STING (STimulator of INterferon Genes) pathway …See details»
AbbVie acquires STING pathway-focused Mavupharma
Jul 15, 2019 · Chicago-based AbbVie has announced its acquisition of Seattle-based oncology drug discovery company Mavupharma, which focuses on STING pathway.See details»
AbbVie Enhances Early Stage Oncology Pipeline with Acquisition …
NORTH CHICAGO, Ill., July 15, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has acquired Seattle -based Mavupharma, a privately held biopharmaceutical company focused on novel...See details»
AbbVie (ABBV) Acquires Mavupharma to Boost Cancer Portfolio
Jul 16, 2019 · AbbVie Inc. ABBV announced that it has acquired Seattle-based, privately held company Mavupharma to develop novel treatments for cancer using the latter’s STING signaling pathway. The...See details»
Mavupharma - Crunchbase
Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases. Coriell Life Sciences delivers the power of precision medicine using pharmacogenomics and clinical decision support software.See details»
Early Stage Oncology Pipeline Enhanced by AbbVie with …
Jul 16, 2019 · AbbVie announced that it has acquired Seattle-based Mavupharma, a privately held biopharmaceutical company focused on novel approaches to target the STING (STimulator of INterferon Genes) pathway for the treatment of cancer.See details»
AbbVie bets on early immuno-oncology asset | BioPharma Dive
Jul 15, 2019 · AbbVie has expanded its oncology pipeline with the acquisition of Mavupharma, a privately held biotech targeting cancer through an immune pathway called STING. The companies did not disclose the terms of the transaction when announcing the deal Monday.See details»
Mavupharma - Funding, Financials, Valuation & Investors
Non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease.See details»
AbbVi acquires Mavupharma and with it MAVU 104, a first-in-class ...
Jul 19, 2019 · AbbVie announced that it has acquired Seattle-based Mavupharma, a privately held biopharmaceutical company focused on novel approaches to target the STING (STimulator of INterferon Genes) pathway for the treatment of cancer.See details»
AbbVie Acquires Mavupharma - American Pharmaceutical Review
Jul 16, 2019 · AbbVie has acquired Seattle-based Mavupharma, a privately held biopharmaceutical company focused on novel approaches to target the STING (STimulator of INterferon Genes) pathway for the treatment of cancer.See details»
AbbVie jumps into STING cancer work with Mavupharma buy
Jul 15, 2019 · STING—or STimulator of INterferon Genes—in a nutshell works to activate the pathway and, it is hoped, kick-start an innate immune response against cancer cells in the tumor microenvironment.See details»
Mavupharma - Contacts, Employees, Board Members, Advisors
Mavupharma has 3 board members and advisors, including James Bristol. Non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease.See details»
Mavupharma Selects First Immuno-Oncology Clinical Candidate
Jan 3, 2019 · Mavupharma (Mavu) announced today that it has selected its first immuno-oncology clinical development candidate, MAVU-104, a novel innate immune modulator.See details»